Katharine O'Connell White

Venova Technologies, Inc.

$249,955

Attributed

$399,988

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $300.1K · FY2022–25

$500K$375K$250K$125K$0

'22

'23

'24

'25

Funding mix

By agency

NIH$399,988 · 2

By mechanism

R41$300,067 · 1

N01$99,921 · 1

Top collaborators

Emily Man1 shared

Most similar at Venova Technologies, Inc.

Same institution · by research overlap

Emily Man$1,658,628

Others in their field

Other Rising Stars on “Woman”

Rebecca Montalvan · Westat, Inc.$86,600,000
James Cappo · National Jewish Health$9,298,220
Debra Burnin · Sri International$9,060,975
April Carson · University Of Mississippi Med Ctr$9,022,104
Iii, Josiah J. Sampson · Tougaloo College$8,000,000
Jacob Sutton Coverstone · Neurovations$6,882,205

Research focus

WomanContraceptive MethodsInnovationSide EffectNational Institute Of Child Health And Human DevelopmentDevicesDesignFirst-In-HumanPregnancyScreeningSafetyContraceptive AgentsLeadFertilityClinical TrialsClinical Research SiteClinical Practice GuidelineBarrier ContraceptionClinical DevelopmentCervix UteriAnatomyAffectContraceptive EfficacyContraceptive Devices

Grant awards (2)

NICHD: R&D: A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION: NON-SEVERABLE$99,921

N01 · FY2025 · HD · contact PI

Development of a novel, non-hormonal female contraceptive device$300,067

R41 · FY2022 · HD